/ /

CLINICAL

‘Ideal’ disease control leads to better nAMD outcomesNeovascular age-related macular degeneration (nAMD) is well-known as a heterogeneous disease with variable natural history and variable treatment response, said Carl D. Regillo, MD, FACS. Many patients do well without monthly treatment as noted in HARBOR PRN arms.
Treat-and-extend may lead to better AMD resultsTreating neovascular age-related macular degeneration (nAMD) patients with anti-vascular endothelial growth factor (anti-VEGF) ranibizumab (Lucentis, Genentech) on a monthly regimen has produced “great results” in clinical trials, said Prof. Mark C. Gillies, MBBS, PhD. “But what happens after that and what happens in real world practice?”
Computer-based image analysis promising for ROPComputers may make more reliable diagnoses of plus disease in retinopathy of prematurity than individual clinicians, a researcher reports.
Paradigm shifting for ILM peeling, prone position after vitrectomyPeeling of the internal limiting membrane has increasingly become a dogma of surgical retina, while maintenance of the face-down positioning may become anachronistic in many cases.
New biomarker may predict treatment response in DMEResearchers have identified a new biomarker they believe can be used as a predictor of vision change in patients with diabetic macular edema, either during the natural history of the disease or after undergoing anti-VEGF therapy. The biomarker is disorganization of the retinal inner layers, or DRIL.
How to manage retinal disease in pregnant patients
How to manage retinal disease in pregnant patientsPregnant patients require special care and surveillance when retinal diseases are present.
It’s about ocular health, not sales
It’s about ocular health, not salesContact lenses are medical devices. I can write it again and again. These are not commodities.
Roles of Klotho and Endothelin-1 in pseudoexfoliationSerum and aqueous levels of Klotho levels are reduced in pseudoexfoliation syndrome (PXF) and pseudoexfoliative glaucoma (PEG) while Endothelin-1 (ET-1) is increased, researchers say.
How glucosamine supplements may increase IOPThe finding raises questions about whether the supplements could play a role in glaucoma, wrote H. Esfandiari of the University of Medical Sciences in Tehran, Iran and colleagues in the journal Eye.
Tracking treatment adherence in newly diagnosed open-angle glaucoma
Tracking treatment adherence in newly diagnosed open-angle glaucomaAn analysis of U.S. claims data reveals a substantial proportion of patients (17%) remained untreated 4 years after their initial diagnosis of open-angle glaucoma.